Machine Learning in Life Sciences Laboratory
University of A Coruña - CITIC
Hi!! We investigate omic data using machine learning to unveil patterns in complex diseases, identify biomarkers, and predict outcomes and drug responses, contributing to the advancement of understanding and personalization in life sciences research.
Research Lines
Bioinformatics
Our team, composed of biologists and bioinformaticians, leverages computational tools to extract meaningful biological insights from a variety of genomic datasets. Our research spans from plant genomics to the study of infectious bacterial diseases, aiming to unravel the molecular mechanisms underlying these biological systems.
Biomedical Data Science
We apply data science techniques to analyze omic datasets, with a particular focus on identifying diagnostic and predictive biomarkers in complex diseases. Our goal is to support personalized medicine approaches by uncovering patterns and associations that inform clinical decision-making.
Omic Integration
Our research focuses on the integration of multi-omic data (genomics, transcriptomics, proteomics, etc.) to understand molecular interactions across different biological layers. By combining diverse datasets, we aim to enhance our understanding of disease mechanisms and improve strategies for diagnosis and treatment.
news
| Jan 15, 2026 | New collab publication available! Interpretable inflammation landscape of circulating immune cells |
|---|---|
| Jan 09, 2026 | New collab publication available! Exploiting the synergy between computational and experimental biophysics for efficient cancer drug development |
| Jan 08, 2026 | New collab publication available! Determination of the presence of pharmacological residues in human feces by liquid chromatography-tandem mass spectrometry |
selected publications
-
A review on machine learning approaches and trends in drug discoveryComputational and Structural Biotechnology Journal, Aug 2021Q1, 70/297 BIO-MB, 6.155 IF -
Community assessment to advance computational prediction of cancer drug combinations in a pharmacogenomic screenNature Communications, Aug 2019Q1, D1, 6/71 MS, 12.121 IF -
Prediction of high anti-angiogenic activity peptides in silico using a generalized linear model and feature selectionScientific Reports, Aug 2018Q1, 15/69 MS, 4.011 IF